Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protalix BioTherapeutics (PLX) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for Protalix BioTherapeutics (PLX) over the last 17 years, with Q3 2025 value amounting to -$2.1 million.

  • Protalix BioTherapeutics' Change in Accured Expenses fell 14614.5% to -$2.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.7 million, marking a year-over-year decrease of 43130.43%. This contributed to the annual value of $696000.0 for FY2024, which is 8685.55% down from last year.
  • As of Q3 2025, Protalix BioTherapeutics' Change in Accured Expenses stood at -$2.1 million, which was down 14614.5% from -$610000.0 recorded in Q2 2025.
  • Over the past 5 years, Protalix BioTherapeutics' Change in Accured Expenses peaked at $3.3 million during Q2 2023, and registered a low of -$3.9 million during Q2 2022.
  • In the last 5 years, Protalix BioTherapeutics' Change in Accured Expenses had a median value of $177000.0 in 2023 and averaged -$24263.2.
  • In the last 5 years, Protalix BioTherapeutics' Change in Accured Expenses soared by 50300.55% in 2023 and then tumbled by 59096.05% in 2024.
  • Quarter analysis of 5 years shows Protalix BioTherapeutics' Change in Accured Expenses stood at $1.3 million in 2021, then tumbled by 127.83% to -$366000.0 in 2022, then surged by 503.01% to $1.5 million in 2023, then decreased by 7.39% to $1.4 million in 2024, then plummeted by 256.59% to -$2.1 million in 2025.
  • Its Change in Accured Expenses was -$2.1 million in Q3 2025, compared to -$610000.0 in Q2 2025 and -$1.3 million in Q1 2025.